APPLICATION
ANDA210689
TYPE
ANDA
ORIGINAL APPROVAL
2019-09-05
LATEST ACTION
2026-04-30
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued
Products
FOSAPREPITANT DIMEGLUMINEDiscontinued
FOSAPREPITANT DIMEGLUMINE EQ 150MG BASE/VIAL · POWDER · INTRAVENOUS
Approval history
2026-04-30Labeling · Supplement 7 · standardAP
2026-04-30Labeling · Supplement 5 · standardAP
2026-04-30Labeling · Supplement 6 · standardAP
2026-04-30Labeling · Supplement 4 · standardAP
2021-01-06Labeling · Supplement 2 · standardAP
2019-09-05UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.